Appeals Court Rules in Favor of Prometheus Laboratories Inc., Upholds the Patentability of Its Claims for Methods of Thiopurine Metabolite Testing

SAN DIEGO, Sept. 17 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in favor of Prometheus in a dispute over the validity of its patents that cover the methods for a diagnostic test that enables physicians to optimize ongoing dosing of thiopurines to reach and maintain desired therapeutic levels (U.S. Patent Nos. 6,355,623 and 6,680,302).

"This clear-cut ruling by the U.S. Court of Appeals for the Federal Circuit did not simply remand but completely reversed the judgment of the U.S. District Court," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "Prometheus is committed to developing and commercializing innovative diagnostics and other products to help physicians improve patient lives. As a key element in enabling this strategy, we have historically taken the strong position that we will vigorously defend any intellectual property rights that we own or license, and we will continue to do the same going forward."

About Prometheus

SOURCE Prometheus Laboratories Inc.

CONTACT: Pete De Spain, Director, Investor Relations & Corporate
Communications of Prometheus Laboratories Inc., +1-858-587-4117,
pdespain@prometheuslabs.com

Web site: http://www.prometheuslabs.com/